Search results for "advanced"

showing 10 items of 750 documents

ICT for external use in Croatian four- and five-star hotels

2016

The Purpose – The objective of the paper is to examine the implementation of advanced technology and promotional supports in hotel companies and to compare their performance in four- and five-star hotels. More specifically, ICT for external use are analysed, i.e. customer relationship management (CRM), communication with customers, promotional supports, and online order receptions. Design/Methodology/Approach – The empirical research took place in 38 upscale (26 four and 12 five-star) hotels located in Croatia, in the regions of Dalmatia, Istria, and Kvarner, and in the city of Zagreb. The data were collected through a structured questionnaire administered mainly during personal interviews …

media_common.quotation_subjectCustomer relationship managementTX901-946.5ict for external usePromotion (rank)Empirical researchSales promotion0502 economics and businessMarketingmedia_commonICT for external use; advanced technology; promotional supports; upscale hotels; Croatia.upscale hotelsbusiness.industry05 social sciencesInformation technologypromotional supportsHospitality industrycroatiaInformation and Communications TechnologyOrder (business)Tourism Leisure and Hospitality Management050211 marketingBusinessICT for external use; advanced technology; promotional supports; upscale hotels; Croatiaadvanced technology050203 business & managementHospitality industry. Hotels clubs restaurants etc. Food serviceTourism and hospitality management
researchProduct

The Association of Basal Insulin Glargine and/or n-3 Fatty Acids With Incident Cancers in Patients With Dysglycemia

2014

OBJECTIVE Epidemiologic studies linking insulin glargine and glucose-lowering therapies to cancers and n-3 fatty acids to cancer prevention have not been confirmed. We aimed to assess the effect of insulin glargine and n-3 fatty acids on incident cancers within the context of the ORIGIN (Outcome Reduction with Initial Glargine Intervention) trial. RESEARCH DESIGN AND METHODS The ORIGIN trial is an international, long-term, randomized two-by-two factorial study comparing insulin glargine with standard care and n-3 fatty acids with placebo (double blind) in people with dysglycemia at high risk for cardiovascular events. The primary outcome measure (cancer substudy) was the occurrence of any …

medicine.medical_specialty2902 Advanced and Specialized NursingEndocrinology Diabetes and Metabolismmedicine.medical_treatment10265 Clinic for Endocrinology and Diabetology610 Medicine & healthContext (language use)law.inventionRandomized controlled triallawInternal medicineDiabetes mellitusInternal MedicinemedicineAdvanced and Specialized NursingCancer preventionInsulin glarginebusiness.industryInsulinCancermedicine.diseaseMetformin2712 Endocrinology Diabetes and MetabolismEndocrinology2724 Internal MedicineNEOPLASIASbusinessmedicine.drugDiabetes Care
researchProduct

Performance of the PRO-C3 collagen neo-epitope biomarker in non-alcoholic fatty liver disease.

2019

Background & Aim There is an unmet need for non-invasive biomarkers in non-alcoholic fatty liver disease (NAFLD) that can diagnose advanced disease and identify patients suitable for clinical trials. The PRO-C3 collagen neo-epitope is a putative direct marker of fibrogenesis. We assessed the performance of PRO-C3 in a large, well-characterised international NAFLD cohort and report the development and validation of 2 novel panels for the diagnosis of advanced fibrosis (F≥3) in NAFLD, including a simplified clinical score which eliminates the need for online calculators. Methods Plasma PRO-C3 levels were determined in a prospectively recruited international cohort of 449 patients with biopsy …

medicine.medical_specialtyADVANCED FIBROSISSCORING SYSTEMPROGRESSIONGastroenterologySTEATOHEPATITIS03 medical and health sciences0302 clinical medicineFibrosisInternal medicineNAFLDBiopsyInternal MedicineImmunology and AllergyMedicineSTEATOSISPRO-C3Stage (cooking)lcsh:RC799-869030304 developmental biologySteatohepatitisRISK0303 health sciencesScience & TechnologyHepatologymedicine.diagnostic_testGastroenterology & Hepatologybusiness.industryFatty liverfibrosisGastroenterologyNASHDIABETES-MELLITUSCHRONIC HEPATITISBiomarkermedicine.disease3. Good healthClinical trialCohortBIOPSYBiomarker (medicine)030211 gastroenterology & hepatologylcsh:Diseases of the digestive system. GastroenterologySteatohepatitisbusinessLife Sciences & BiomedicineResearch ArticleJHEP reports : innovation in hepatology
researchProduct

Abstract 3420: High-sensitivity Troponin T Improves Cardiovascular Risk Prediction In Patients With Cerebral Ischemia

2012

Background Patients with a cerebral ischemic event are at high risk of recurrent ischemia and other cardiovascular events. Clinical scores are recommended to predict cardiovascular risk in patients with cerebral ischemia to inform secondary preventive measures. Biomarkers may improve risk prediction beyond clinical scores and therefore secondary prevention. Methods Within the observational Find-AF trial (ISRCTN 46104198), 197 patients aged >18 years with cerebral ischemia and without atrial fibrillation had blood sampled at baseline and completed 1-year follow-up. Predictive value of 5 novel cardiovascular biomarkers for a combined vascular endpoint (acute coronary syndrome, stroke, car…

medicine.medical_specialtyAcute coronary syndromeIschemia030204 cardiovascular system & hematology03 medical and health sciences0302 clinical medicineModified Rankin ScaleInternal medicineMedicineStrokeAdvanced and Specialized NursingbiologyTroponin Tbusiness.industryHazard ratioAtrial fibrillationmedicine.diseaseTroponin3. Good healthSurgerybiology.proteinCardiologyNeurology (clinical)Cardiology and Cardiovascular Medicinebusiness030217 neurology & neurosurgeryStroke
researchProduct

Interdisciplinary Screening, Diagnosis, Therapy and Follow-up of Breast Cancer. Guideline of the DGGG and the DKG (S3-Level, AWMF Registry Number 032…

2018

Geburtshilfe und Frauenheilkunde 78(11), 1056-1088 (2018). doi:10.1055/a-0646-4630

medicine.medical_specialtyAdvanced breastPsychological interventionGuideline/LeitlinieSystemic therapymetastasiertes Mammakarzinomprimary breast cancer03 medical and health sciences0302 clinical medicineBreast cancerbreast cancerMaternity and MidwiferyBrustkrebsMedicineprimäres Mammakarzinom030212 general & internal medicineGebFra ScienceIntensive care medicineLeitlinietherapybusiness.industryTumor biologyObstetrics and GynecologyCancerGuidelinemedicine.diseaseMetastatic breast cancerddc:030220 oncology & carcinogenesismetastatic breast cancerbusinessTherapieguideline
researchProduct

Liraglutide Increases the Catabolism of Apolipoprotein B100–Containing Lipoproteins in Patients With Type 2 Diabetes and Reduces Proprotein Convertas…

2021

OBJECTIVE Dyslipidemia observed in type 2 diabetes (T2D) is atherogenic. Important features of diabetic dyslipidemia are increased levels of triglyceride-rich lipoproteins and small dense LDL particles, which all have apolipoprotein B100 (apoB100) as a major apolipoprotein. This prompted us to study the effect of the GLP-1 agonist liraglutide on the metabolism of apoB100-containing lipoproteins. RESEARCH DESIGN AND METHODS We performed an in vivo kinetic study with stable isotopes (L-[1-13C]leucine) in 10 patients with T2D before and after 6 months of treatment with liraglutide (1.2 mg/day). We also evaluated in mice the effect of liraglutide on the expression of genes involved in apoB100-…

medicine.medical_specialtyApolipoprotein BEndocrinology Diabetes and MetabolismLipoproteinsAdipose tissue030209 endocrinology & metabolismLipoproteins VLDL03 medical and health sciencesMice0302 clinical medicineInternal medicineInternal MedicinemedicineAnimalsHumans030212 general & internal medicineSubtilisinsAdvanced and Specialized NursingbiologyCatabolismLiraglutidebusiness.industryPCSK9Liraglutidemedicine.diseaseLipoproteins LDLEndocrinologyDiabetes Mellitus Type 2biology.proteinKexinProprotein Convertase 9businessRetinol-Binding Proteins PlasmaDyslipidemiamedicine.drugLipoprotein
researchProduct

Autonomic dysfunction in a group of lower extremities arterial disease outpatients.

2021

Background: The understanding of the specific role of sympathetic neural control and dysregulation in lower extremities arterial disease (LEAD) is still very limited. Aim of our study was to investigate the autonomic profile in LEAD patients and to evaluate if the eventual autonomic alterations were more severe in patients with advanced disease. Methods: We enrolled all consecutive outpatients with LEAD referred to our Departments between July 2012 and September 2014. They were compared to a group of matched outpatients without LEAD. All patients underwent Holter ECG monitoring. Time-domain analysis of heart rate variability (HRV) was evaluated. Results: Compared to controls, patients with …

medicine.medical_specialtyArterial diseasebusiness.industrySevere diseaseDiseaseAutonomic Nervous SystemLower ExtremityHeart RateInternal medicineOutpatientsAdvanced diseaseCardiologyElectrocardiography AmbulatoryMedicineHeart rate variabilityHumansStage (cooking)Cardiology and Cardiovascular MedicineLead (electronics)businessHumanHolter ecgMinerva cardiology and angiology
researchProduct

Atrial fibrillation: a geriatric perspective on the 2020 ESC guidelines

2021

Key Summary Points Aim To provide a geriatric perspective on the 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio–Thoracic Surgery (EACTS). Findings While the large majority of AF patients in real life are older, frail and cognitively impaired, these are mostly excluded from clinical trials, and physicians’ attitudes often prevail over standardized algorithms. On the basis of existing evidence, we suggest that (1) opportunistic AF screening by pulse palpation or ECG rhythm strip is cost-effective, and (2) whereas advanced chronological age by itself is not a contraindication to AF treatment, a Comp…

medicine.medical_specialtyAtrial fbrillation · Advanced age · Older patients · Anticoagulation · Cognitive impairmentClinical Decision-MakingCardiologyManagement of atrial fibrillationReviewPalpationAnticoagulationOlder patientsOlder patientsHumansMedicineIntensive care medicineGeriatric AssessmentContraindicationAgedFrailtymedicine.diagnostic_testbusiness.industryPerspective (graphical)Atrial fibrillationAdvanced agemedicine.diseaseAtrial fibrillationClinical trialCognitive impairmentAdvanced age; Anticoagulation; Atrial fibrillation; Cognitive impairment; Older patientsCardiothoracic surgerybusiness
researchProduct

Bisphosphonate-related osteonecrosis of the jaw (BRONJ): run dental management designs and issues in diagnosis

2007

Recently, jawbone osteonecrosis has been largely reported as a potential adverse effect of bisphosphonate (BP) administration. Because of the peculiar pharmacokinetic and pharmacodynamic features of the BF (mainly for i.v. administration), their efficacy and large use, some major issues have to be taken into account extendedly both by oncologists and by dentists: 1) therapeutic dental protocol for patients with diagnosis of bisphosphonate-related osteonecrosis of the jaw (BRONJ); 2) dental strategies for patients in former or current i.v. BF treatment and in absence of BRONJ signs; 3) strategies for patients before i.v. BF treatment. Clinical features and guidelines for the management of th…

medicine.medical_specialtyBone diseasemedicine.medical_treatmentDentistryBone NeoplasmsJaw neoplasmPatient Education as TopicmedicineHumansDental Restoration PermanentIntensive care medicineAdverse effectbisphosphonates metastatic bone diseaseBone Density Conservation AgentsDiphosphonatesbusiness.industrySurrogate endpointAdvanced stageOsteonecrosisHematologyBisphosphonatemedicine.diseaseJaw NeoplasmsOncologybusinessOsteonecrosis of the jawAnnals of Oncology
researchProduct

Dose-finding study of oxaliplatin associated to capecitabinebased preoperative chemoradiotherapy in locally advanced rectal cancer

2018

// Gemma Bruera 1, 2 , Mario Di Staso 3 , Pierluigi Bonfili 3 , Antonio Galvano 4 , Rosa Manetta 5 , Gino Coletti 6 , Roberto Vicentini 7 , Stefano Guadagni 2, 8 , Corrado Ficorella 2, 9 , Ernesto Di Cesare 2, 3 , Antonio Russo 4 and Enrico Ricevuto 1, 2 1 Oncology Territorial Care, S. Salvatore Hospital, Oncology Network ASL1 Abruzzo, University of L'Aquila, L'Aquila, Italy 2 Department of Biotechnological and Applied Clinical Sciences, University of L’Aquila, L’Aquila, Italy 3 Radiotherapy, S. Salvatore Hospital, Oncology Network ASL1 Abruzzo, University of L’Aquila, L’Aquila, Italy 4 Medical Oncology, Department of Surgical, Oncological and Stomatological Sciences, University of Palermo,…

medicine.medical_specialtyCapecitabine; Chemoradiotherapy; Dose-finding; Locally advanced rectal cancer; Oxaliplatin; OncologyColorectal cancerSettore MED/06 - Oncologia Medicamedicine.medical_treatmentRectumchemoradiotherapyCapecitabine03 medical and health sciences0302 clinical medicinelocally advanced rectal cancermedicineMucositisbusiness.industryGeneral surgerycapecitabineoxaliplatinmedicine.diseaseOxaliplatinRadiation therapyRegimenmedicine.anatomical_structureOncology030220 oncology & carcinogenesisdose-findingClinical Research Paperbusiness030217 neurology & neurosurgeryChemoradiotherapymedicine.drug
researchProduct